drugset / Trial / NCT04419909

Retreatment With CTL019/CTL119

NCT04419909

Phase 1 Not yet recruiting 12 enrolled University of Pennsylvania
NaSingle-groupOpen-labelTreatment

Summary

This research study is designed to evaluate the effects of retreatment with CTL019/CTL119 in patients with late relapse of B-cell lymphomas.

Timeline

Start
2026-05
Primary completion
2028-07
Completion
2028-07

Drugs

EvaluationDrugModalityDoseRoute
Subject CTL119 Cell therapy
Subject Tisagenlecleucel Cell therapy